Albuminuria in Hypertensive Patients: Where the Choice of Antihypertensive Medications Matters:

Mani, Arya

doi:10.1111/jch.12660

Cited by 5 publications

(3 citation statements)

References 14 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants with severe ACR/PCR elevations were more likely to have uncontrolled BP at both targets compared to those without significant elevations in ACR/PCR. Koroshi proposes that high blood pressure may cause microalbuminuria by increasing glomerular filtration pressure and subsequent renal damage [23] and other data have linked BP control to a reduction in urine albumin levels [24]. The effect of BP control may be mediated through albuminuria or proteinuria, and Mani [24] has reported that BP control without improvement in albuminuria/proteinuria did not have an adequate effect in slowing the progression of CKD.…”

Section: Discussionmentioning

confidence: 99%

“…Koroshi proposes that high blood pressure may cause microalbuminuria by increasing glomerular filtration pressure and subsequent renal damage [23] and other data have linked BP control to a reduction in urine albumin levels [24]. The effect of BP control may be mediated through albuminuria or proteinuria, and Mani [24] has reported that BP control without improvement in albuminuria/proteinuria did not have an adequate effect in slowing the progression of CKD. Many studies also show that that albuminuria or proteinuria are strong and independent predictors of the risks of CKD progression, CVD and all-cause mortality [25–29].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia

et al. 2019

View full text Add to dashboard Cite

Background High blood pressure is the most significant risk factor for the development and progression of chronic kidney disease (CKD). Lowering blood pressure is a goal to prevent CKD progression. This study of adults with CKD who have hypertension aimed to determine blood pressure control rates and the treatment patterns of hypertension and to explore factors associated with control of hypertension. Methods This cross-sectional study included all non-dialysis people with CKD stages 3A to 5 under nephrology care in three public renal clinics in Queensland, who joined the CKD.QLD registry from May 2011 to Dec 2015 and had a history of hypertension. Demographic information, other health conditions, laboratory markers and anti-hypertensive medications in use at consent were extracted from the registry. Results Among 1814 CKD people in these three sites in the registry who were age ≥ 18 years and had CKD stage 3A to 5, 1750 or 96% had a history of hypertension. Of these, the proportion with BP control to < 140/90 mmHg was 61.7% and to < 130/80 mmHg was 36.3%. With target BP < 140/90 mmHg or < 130/80 mmHg, participants aged ≥65 years were 1.23 (95% CI 1.06–1.42) or 1.12 (1.03–1.22) times more likely to have uncontrolled BP compared to those < 65 years old. Participants with severe albuminuria or proteinuria were 1.58 (1.32–1.87) or 1.28 (1.16–1.42, p < 0.001) more likely to have uncontrolled BP compared to those without significant albuminuria or proteinuria. Participants who had cardiovascular disease (CVD) were less likely to have uncontrolled BP compared to those without CVD (0.78, 0.69–0.89 or 0.86, 0.80–0.92). Factors associated with use of more classes of antihypertensive medicines among participants with uncontrolled BP (> 140/90 mmHg) were older age, diabetes, CVD, obesity and severe albuminuria/proteinuria ( p < 0.05). Renin Angiotensin Aldosterone System inhibitors were the most frequently used medicines, regardless of the number of medicine classes an individual was prescribed. Conclusions Blood pressure control rates in these hypertensive people with CKD was still far from optimal. People with CKD and hypertension aged 65 or older or with severe albuminuria or proteinuria, a group at risk of progression of kidney disease, have higher rates of uncontrolled BP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This is consistent with the inclusion of evidence on the effect of sodium reduction on blood pressure in individuals with untreated hypertension in the assessment (Section 5.5.1.2). The Panel notes that prevalence proportions of albuminuria (urine albumin ≥ 30 mg/24 hour) of 40% or more have been reported in untreated hypertensive populations (Mani, 2016;Maggon et al, 2018).…”

Section: Panel Consideration Of the Comment Receivedmentioning

confidence: 99%

Outcome of public consultations on the Scientific Opinions of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on Dietary Reference Values for sodium and chloride

2019

EFSA Supporting Publications

View full text Add to dashboard Cite

The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the draft Scientific Opinions on Dietary Reference Values (DRVs) for sodium and chloride, prepared by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA Panel) and endorsed by the Panel for public consultation at its Plenary meeting on 13 March 2019. The written public consultations for these documents were open from 3 April 2019 to 22 May 2019. No comments were received on the draft Scientific Opinion on DRVs for chloride. On the draft Scientific Opinion on DRVs for sodium, EFSA received comments from eight interested parties and three individuals in their personal capacity. EFSA and its NDA Panel wish to thank all stakeholders for their contributions. The current report summarises the outcome of the public consultations and includes a summary of the comments received and how the comments were addressed. The NDA Panel prepared an updated version of the Scientific Opinion on DRVs for sodium taking into account the comments received. The Scientific Opinions were adopted at the NDA Plenary meeting on 3 July 2019 and are published in the EFSA Journal.

show abstract

Statin use, albuminuria, and mortality risk: Re-evaluating C-reactive protein to albumin ratio in hypertensive patients based on NHANES data

Hung,

Chao

2024

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Albuminuria in Hypertensive Patients: Where the Choice of Antihypertensive Medications Matters:

Cited by 5 publications

References 14 publications

Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia

Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia

Outcome of public consultations on the Scientific Opinions of the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) on Dietary Reference Values for sodium and chloride

Statin use, albuminuria, and mortality risk: Re-evaluating C-reactive protein to albumin ratio in hypertensive patients based on NHANES data

Contact Info

Product

Resources

About